Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
8.1
4.9
Journals
IJMS
Special Issues
Bioactive Medicinal Products in the Prevention and Treatment of Pulmonary...
ijms-logo
Submit to IJMS Review for IJMS Propose a Special Issue

Journal Menu

► Journal Menu

Journal Browser

► Journal Browser
share announcement

Bioactive Medicinal Products in the Prevention and Treatment of Pulmonary Disease

A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Bioactives and Nutraceuticals".

Deadline for manuscript submissions: closed (31 August 2023) | Viewed by 4335

Special Issue Editor

Dr. Aggeliki S. Rapti

E-Mail Website
Guest Editor
2nd Pulmonary Department, Hospital of Chest Diseases of Athens, 11527 Athens, Greece
Interests: lung cancer; sarcoidosis-interstitial lung diseases; COPD-pulmonary rehabilitation

Special Issue Information

Dear Colleagues, 

Bioactive compounds from nature, especially medicinal plants, have been used in natural medicines worldwide as therapeutics and prevention agents. Many plants are known to contain various active principles of therapeutic value to cure various diseases and are also used in various therapies related to lung diseases. Examples of some plants used in the treatment of lung diseases are Papaver somniferum for cough and cramps; Lobella spp. for asthma; and Ephedra spp. in respiratory alignments. There is an increasing interest in the clinical evidence of bioactive compounds in respiratory inflammatory disorders such as chronic bronchitis, pulmonary diseases, and asthma. Moreover, isoquinoline alkaloids and their role in reducing the various factors leading to idiopathic pulmonary fibrosis provide a promising therapeutic approach.

Lung inflammation involves the release of inflammatory mediators, which causes several abnormalities in the lungs. Natural products target the epithelial-mesenchymal transition, oxidative stress, fibroblast activation, inflammatory injury, metabolic regulation, and extracellular matrix accumulation. In addition, several compounds such as epigallocatechin, gallocatechin gallate, berberine, berbamine, coptisine, and dicentrine were reported to be involved in the inhibition of viral replication, by inhibiting the viral life cycle in the host and acting against viral-induced respiratory inflammation.

This Special Issue, entitled “Bioactive Medicinal Products in the Prevention and Treatment of Pulmonary Disease”, will provide reviews and original research about novel advances in the development and application of bioactive compounds, and pharmacological evidence in relation to respiratory diseases.

Dr. Aggeliki S. Rapti
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • bioactive medicinal products
  • medical herbs
  • pneumonia
  • isoquinoline
  • berberine
  • pulmonary fibrosis

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

22 pages, 3501 KiB  
Article
Effects of Green Tea Polyphenol Epigallocatechin-3-Gallate on Markers of Inflammation and Fibrosis in a Rat Model of Pulmonary Silicosis
by Jana Adamcakova, Sona Balentova, Romana Barosova, Juliana Hanusrichterova, Pavol Mikolka, Kristian Prso, Juraj Mokry, Zuzana Tatarkova, Dagmar Kalenska and Daniela Mokra
Int. J. Mol. Sci. 2023, 24(3), 1857; https://doi.org/10.3390/ijms24031857 - 17 Jan 2023
Cited by 1 | Viewed by 2298
Abstract
Inhalation of silica particles causes inflammatory changes leading to fibrotizing silicosis. Considering a lack of effective therapy, and a growing information on the wide actions of green tea polyphenols, particularly epigallocatechin-3-gallate (EGCG), the aim of this study was to evaluate the early effects [...] Read more.
Inhalation of silica particles causes inflammatory changes leading to fibrotizing silicosis. Considering a lack of effective therapy, and a growing information on the wide actions of green tea polyphenols, particularly epigallocatechin-3-gallate (EGCG), the aim of this study was to evaluate the early effects of EGCG on markers of inflammation and lung fibrosis in silicotic rats. The silicosis model was induced by a single transoral intratracheal instillation of silica (50 mg/mL/animal), while controls received an equivalent volume of saline. The treatment with intraperitoneal EGCG (20 mg/kg, or saline in controls) was initiated the next day after silica instillation and was given twice a week. Animals were euthanized 14 or 28 days after the treatment onset, and the total and differential counts of leukocytes in the blood and bronchoalveolar lavage fluid (BALF), wet/dry lung weight ratio, and markers of inflammation, oxidative stress, and fibrosis in the lung were determined. The presence of collagen and smooth muscle mass in the walls of bronchioles and lung vessels was investigated immunohistochemically. Early treatment with EGCG showed some potential to alleviate inflammation, and a trend to decrease oxidative stress-induced changes, including apoptosis, and a prevention of fibrotic changes in the bronchioles and pulmonary vessels. However, further investigations should be undertaken to elucidate the effects of EGCG in the lung silicosis model in more detail. In addition, because of insufficient data from EGCG delivery in silicosis, the positive and eventual adverse effects of this herbal compound should be carefully studied before any preventive use or therapy with EGCG may be recommended. Full article
(This article belongs to the Special Issue Bioactive Medicinal Products in the Prevention and Treatment of Pulmonary Disease)
►▼ Show Figures

Figure 1

9 pages, 2043 KiB  
Article
Cirsilineol Treatment Attenuates PM2.5-Induced Lung Injury in Mice
by Chaeyeong Kim, Go Oun Kim and Jong-Sup Bae
Int. J. Mol. Sci. 2022, 23(22), 13948; https://doi.org/10.3390/ijms232213948 - 12 Nov 2022
Cited by 1 | Viewed by 1439
Abstract
Ultrafine particulate matter with less than 2.5 μm diameter (PM2.5) is an air pollutant that causes severe lung damage. Currently, effective treatment and preventive methods for PM2.5-induced lung damage are limited. Cirsilineol (CSL) is a small natural compound isolated [...] Read more.
Ultrafine particulate matter with less than 2.5 μm diameter (PM2.5) is an air pollutant that causes severe lung damage. Currently, effective treatment and preventive methods for PM2.5-induced lung damage are limited. Cirsilineol (CSL) is a small natural compound isolated from Artemisia vestita. In this study, the efficacy of CSL on PM2.5-induced lung toxicity was tested, and its mechanism was identified. Lung injury was caused by intratracheal administration of PM2.5 suspension in animal models. Two days after PM2.5 pretreatment, CSL was injected via mouse tail vein for two days. The effects of CSL on PM2.5-induced lung damage, autophagy, apoptosis, and pulmonary inflammation in a mouse model and their mechanisms were investigated. CSL significantly suppressed histological lung damage and lung wet/dry weight proportion. CSL also significantly reduced PM2.5-induced autophagy dysfunction, apoptosis, lymphocyte suppression, and inflammatory cytokine levels in bronchoalveolar fluid (BALF). Furthermore, CSL increased mammalian target of rapamycin (mTOR) phosphorylation and significantly inhibited the expression of Toll-like receptors (TLR) 2 and 4, MyD88, and the autophagy proteins, Beclin1 and LC3II. Thus, CSL exerts protective effects on pulmonary damage by regulating mTOR and TLR2,4–myD88 autophagy pathways. Therefore, CSL can be used as an effective treatment for PM2.5-induced lung damage. Full article
(This article belongs to the Special Issue Bioactive Medicinal Products in the Prevention and Treatment of Pulmonary Disease)
►▼ Show Figures

Graphical abstract

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop